30 Day Countdown, page-9

I think Neuren meets the following criteria:

From: http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=115

However, recent advances in drug development, particularly for targeted therapies (for example, therapies aimed at patients who have certain biological features, such as the presence of a particular gene mutation), have produced drugs that show dramatic benefit at very early stages in the clinical testing process. The emergence of these therapies led many to question the traditional approach to drug development and approval. The FDA acknowledged these issues in a 2011 report, "Driving Biomedical Innovation: Initiatives to Improve Products for Patients," in which the agency also described the potential creation of a rapid drug development pathway for targeted therapies as a key priority.

GLTAH